VBI Vaccines Inc VBIVQ

Healthcare Biotechnology

VBI Vaccines Inc. is a commercial-stage biopharmaceutical company. Through its approach to virus-like particles (VLPs), including an enveloped VLP (eVLP) platform technology and a proprietary mRNA-launched eVLP (MLE) platform technology, the Company develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. The Company is focused on targeting and overcoming significant infectious diseases, including hepatitis B (HBV), coronaviruses, and cytomegalovirus (CMV), as well as aggressive cancers including glioblastoma (GBM). Its product pipeline includes an approved vaccine and multiple late- and early-stage investigational programs. PreHevbrio is its approved vaccine for hepatitis B. Its Prophylactic Candidates for coronavirus disease include VBI-2901, VBI-2905, VBI-2902, and others. VBI-1501 is its Prophylactic Candidate for cytomegalovirus. VBI-2601 and VBI-1901 are the therapeutic candidates for HBV and GBM.

GREY:VBIVQ - Post by User

VBI Vaccines Inc

Bullboard Posts

Post by ziggy1on Jul 06, 2016 1:26pm

305 Views

Post# 25028130

Just dumped all my shares of VBI.

This crapp went from $86 down to $3 and change (still falling). And their only claim to fame is to say "They're working on ZIKA." Weak...................

Bullboard Posts

Golden Minerals closes Yoquivo gold-silver project sale